To achieve the objectives the Group has set for 2025, R&D has developed an initial three-year action plan that focuses on three core activities…
Servier organizes its R&D in 5 large therapeutic areas where it has extensive know-how and recognized expertise and in which there are important unmet needs of patients: cardiovascular, immune-inflammatory and neuropsychiatric diseases, as well as cancer and diabetes. Servier draws on the excellence of its 2,900 R&D employees worldwide to develop effective treatment solutions.
of revenue from brand-name medicines invested in R&D each year on average
Servier intends to dedicate 50% of its global R&D budget* to researching cancer treatments
* brand-name activity
active alliances worldwide
Founded in 2000 and based in Denmark, Symphogen is a biotech company that has developed an efficient discovery and research platform that can rapidly identify high quality monoclonal and bi-specific antibodies supported by early development capabilities with strong in vitro and in vivo capacities across oncology and immuno-oncology. Symphogen is organized as a combined project and line organization with various research, pre-clinical, CMC (Chemistry, Manufacturing and Control), clinical and regulatory departments.
As part of the acquisition by Servier, Symphogen becomes the antibody center of excellence of the Group as its platform can deliver antibodies with unique functionalities providing best or first in class potential.
READ MORE →